Literature DB >> 9926971

Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy.

K G Kerr1, H T Armitage, P H McWhinney.   

Abstract

Use of fluoroquinolones for antimicrobial prophylaxis during neutropenia is often cited as a significant predisposing factor for viridans group streptococcus (VGS) bacteraemia. Newer compounds in this class are reputed to have enhanced activity against Gram-positive bacteria, and we determined the minimal inhibitory concentrations (MICs) for ciprofloxacin and three of the newer compounds: trovafloxacin, fleroxacin and clinafloxacin, against 44 isolates of VGS. On a gravimetric basis, clinafloxacin was most active (MIC90 0.19 mg/l), whereas ciprofloxacin and fleroxacin were the least active (both MIC90 16 mg/l). Clinafloxacin warrants further study as an agent of prophylaxis against bacterial infection in neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9926971     DOI: 10.1007/s005200050219

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

1.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.

Authors:  H Oh; N El Amin; T Davies; P C Appelbaum; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.

Authors:  B S Sohn; D H Yoon; S Kim; K Lee; E H Kang; J S Park; D H Lee; S H Kim; J Huh; C Suh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-04       Impact factor: 3.267

Review 4.  Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.

Authors:  Dong-Gun Lee; Sung-Han Kim; Soo Young Kim; Chung-Jong Kim; Wan Beom Park; Young Goo Song; Jung-Hyun Choi
Journal:  Korean J Intern Med       Date:  2011-06-01       Impact factor: 3.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.